MPM Oncology Impact Management
Latest statistics and disclosures from MPM BioImpact's latest quarterly 13F-HR filing:
- Top 5 stock holdings are CGEM, INSM, OLMA, ITOS, CRNX, and represent 39.50% of MPM BioImpact's stock portfolio.
- Added to shares of these 10 stocks: MIRM (+$17M), GH (+$14M), ALKS (+$13M), LNTH (+$12M), HLVX (+$9.3M), IRON (+$8.8M), SRRK (+$8.6M), OLMA (+$7.6M), RNAC (+$7.0M), INSM (+$5.7M).
- Started 10 new stock positions in MIRM, SRRK, IMTX, LNTH, HLVX, RNA, GH, RNAC, ALLK, ALKS.
- Reduced shares in these 8 stocks: GERN (-$35M), VRDN (-$11M), , Immatics, STRO, VKTX, Flamel Technologies Sa, ZNTL.
- Sold out of its positions in FOLD, GERN, VRDN, Immatics.
- MPM BioImpact was a net buyer of stock by $94M.
- MPM BioImpact has $644M in assets under management (AUM), dropping by 3.46%.
- Central Index Key (CIK): 0001687078
Tip: Access up to 7 years of quarterly data
Positions held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for MPM BioImpact
MPM BioImpact holds 44 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Cullinan Therapeutics Common (CGEM) | 20.7 | $133M | 7.6M | 17.44 |
|
|
| Insmed Incorporated Common (INSM) | 6.4 | $41M | +15% | 615k | 67.00 |
|
| Olema Pharmaceuticals Common (OLMA) | 4.5 | $29M | +35% | 2.7M | 10.82 |
|
| iTeos Therapeutics Common (ITOS) | 4.0 | $26M | 1.7M | 14.84 |
|
|
| Crinetics Pharmaceuticals Common (CRNX) | 3.9 | $25M | +15% | 557k | 44.79 |
|
| Madrigal Pharmaceuticals Common (MDGL) | 3.1 | $20M | +15% | 71k | 280.16 |
|
| Iovance Biotherapeutics Common (IOVA) | 2.9 | $19M | +7% | 2.4M | 8.02 |
|
| Natera Common (NTRA) | 2.9 | $19M | 175k | 108.29 |
|
|
| Mirum Pharmaceuticals Common (MIRM) | 2.6 | $17M | NEW | 493k | 34.19 |
|
| Ultragenyx Pharmaceutical Common (RARE) | 2.4 | $16M | +54% | 381k | 41.10 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 2.3 | $15M | +15% | 343k | 43.97 |
|
| Guardant Health Common (GH) | 2.2 | $14M | NEW | 500k | 28.88 |
|
| Disc Medicine Common (IRON) | 2.1 | $14M | +175% | 306k | 45.07 |
|
| Alkermes Common (ALKS) | 2.1 | $13M | NEW | 558k | 24.10 |
|
| Edgewise Therapeutics Common (EWTX) | 2.1 | $13M | +67% | 741k | 18.01 |
|
| ALX Oncology Holdings Common (ALXO) | 2.0 | $13M | +71% | 2.2M | 6.03 |
|
| Morphic Holding Common (MORF) | 2.0 | $13M | +13% | 369k | 34.07 |
|
| Lantheus Holdings Common (LNTH) | 1.9 | $12M | NEW | 150k | 80.29 |
|
| Revolution Medicines Common (RVMD) | 1.7 | $11M | +5% | 289k | 38.81 |
|
| Avadel Pharmaceuticals Sponsored ADR | 1.7 | $11M | -10% | 783k | 14.06 |
|
| Xeris Biopharma Holdings Common (XERS) | 1.7 | $11M | +15% | 4.8M | 2.25 |
|
| Axsome Therapeutics Common (AXSM) | 1.7 | $11M | +15% | 132k | 80.50 |
|
| Kalvista Pharmaceuticals Common (KALV) | 1.6 | $10M | +15% | 882k | 11.78 |
|
| Intellia Therapeutics Common (NTLA) | 1.5 | $9.9M | +2% | 444k | 22.38 |
|
| Hillevax Common (HLVX) | 1.4 | $9.3M | NEW | 645k | 14.46 |
|
| Akero Therapeutics Common (AKRO) | 1.4 | $9.1M | +15% | 386k | 23.46 |
|
| 89Bio Common (ETNB) | 1.4 | $9.0M | +15% | 1.1M | 8.01 |
|
| Fulcrum Therapeutics Common (FULC) | 1.4 | $9.0M | +27% | 1.4M | 6.20 |
|
| Sutro Biopharma Common (STRO) | 1.4 | $8.9M | -25% | 3.0M | 2.93 |
|
| Scholar Rock Holding Corp Common (SRRK) | 1.3 | $8.6M | NEW | 1.0M | 8.33 |
|
| Relay Therapeutics Common (RLAY) | 1.3 | $8.3M | +53% | 1.3M | 6.52 |
|
| Cartesian Therapeutics Common (RNAC) | 1.1 | $7.0M | NEW | 260k | 27.01 |
|
| Regenxbio Common (RGNX) | 1.0 | $6.5M | 557k | 11.70 |
|
|
| Viking Therapeutics Common (VKTX) | 1.0 | $6.3M | -20% | 119k | 53.01 |
|
| Zentalis Pharmaceuticals Common (ZNTL) | 0.9 | $5.9M | -4% | 1.5M | 4.09 |
|
| Werewolf Therapeutics Common (HOWL) | 0.9 | $5.8M | 2.4M | 2.44 |
|
|
| Repare Therapeutics Common (RPTX) | 0.8 | $5.4M | 1.6M | 3.30 |
|
|
| Avidity Biosciences Common (RNA) | 0.8 | $5.1M | NEW | 125k | 40.85 |
|
| Compass Therapeutics Common (CMPX) | 0.8 | $5.0M | +153% | 5.0M | 1.00 |
|
| Adaptimmune Therapeutics Sponsored ADR (ADAP) | 0.8 | $5.0M | 5.1M | 0.97 |
|
|
| Immatics NV Common (IMTX) | 0.8 | $4.9M | NEW | 418k | 11.62 |
|
| Trevi Therapeutics Common (TRVI) | 0.7 | $4.5M | +12% | 1.5M | 2.98 |
|
| Verve Therapeutics Common (VERV) | 0.5 | $3.1M | 638k | 4.88 |
|
|
| Allakos Common (ALLK) | 0.1 | $345k | NEW | 345k | 1.00 |
|
Past Filings by MPM BioImpact
SEC 13F filings are viewable for MPM BioImpact going back to 2019
- MPM BioImpact 2024 Q2 filed Aug. 14, 2024
- MPM BioImpact 2024 Q1 filed May 15, 2024
- MPM BioImpact 2023 Q3 filed Nov. 14, 2023
- BioImpact Capital 2023 Q2 filed Aug. 14, 2023
- BioImpact Capital 2023 Q1 filed May 12, 2023
- BioImpact Capital 2022 Q4 filed Feb. 14, 2023
- BioImpact Capital 2022 Q3 filed Nov. 14, 2022
- BioImpact Capital 2022 Q2 filed Aug. 11, 2022
- BioImpact Capital 2022 Q1 filed May 13, 2022
- BioImpact Capital 2021 Q4 filed Feb. 11, 2022
- BioImpact Capital 2021 Q3 filed Nov. 15, 2021
- MPM Oncology Impact Management 2021 Q2 filed Aug. 13, 2021
- MPM Oncology Impact Management 2021 Q1 filed May 13, 2021
- MPM Oncology Impact Management 2020 Q4 restated filed Feb. 24, 2021
- MPM Oncology Impact Management 2020 Q4 filed Feb. 16, 2021
- MPM Oncology Impact Management 2020 Q3 restated filed Nov. 19, 2020